$ARNA News
Last published 7mo ago
- 7mo agoLBPHARNAKYTHSensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual ReportBusiness WireGJB2-GT (SENS-601) CTA/IND-enabling studies progress, supported by regulatory interactions with FDA and EMA since Q3 2025, and on track for CTA submission in H1 2026 SENS-501 Audiogene trial ongoing; six-month
- 1y agoARNASensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year ReportBusiness WireAchieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company's gene therapy candidate being developed to treat a specific form of congenital
- 1y agoLBPHARNAKYTHAGN+1Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent DirectorBusiness WireRegulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today
- 4y agoARNAA Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis - NCT05287126ClinicalTrials.govProportion of Participants Achieving Clinical Remission as Assessed by Modified Mayo Score (MMS) at Week 52, Plasma Concentration of Etrasimod at 4 Hours Post-dose (C4h), Plasma Steady State Trough Concentration (Ctrough,ss) of Etrasimod, (and 15 more...)
- 4y agoARNAArena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program UpdatesBusiness Wire– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Ke
- 4y agoARNAArena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commence
- 4y agoARNAArena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets. About Arena Pharmaceuticals
- 4y agoARNAArena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement restricted stock units ("RSUs") to new employees. The inducement RSUs have a grant date and vesting commencement date
- 4y agoARNAArena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 16 new employees 28,659 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commence
- 4y agoARNAFLOWGIIXNMMCMoore Kuehn Encourages NMMC, FLOW, ARNA, and GIIX Investors to Contact Law FirmPR NewswireNEW YORK, Dec. 16, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shar
- 4y agoHOGPFESIVBXOM+18Stocks making the biggest moves midday: Harley-Davidson, GameStop, SVB Financial, Coca-Cola and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 4y agoARNABLUBLUEFHTX+1Thinking about buying stock in Arena Pharmaceuticals, Bellus Health, Foghorn Therapeutics, Hexo Corp, or bluebird bio?PR NewswireNEW YORK, Dec. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARNA, BLU, FHTX, HEXO, and BLUE. T
- 4y agoHOGPFEBNTXARNA+16Stocks making the biggest moves in the premarket: Harley-Davidson, Arena Pharmaceuticals, Peloton and moreCNBCThe stocks making the biggest moves in premarket trading include Harley-Davidson, Arena Pharmaceuticals, Peloton, and more.
- 4y agoARNAPFEPfizer to Acquire Arena PharmaceuticalsBusiness WireProposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases Expands innovative pipeline potentially enhancing growth through 2025 and beyo
- 4y agoARNAA Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction - NCT05139615ClinicalTrials.govChange From Baseline in Cardiac Index Measured by Right Heart Catheterization (RHC), Change From Baseline in Cardiac Output Measured by RHC, Change From Baseline in Pulmonary Capillary Wedge Pressure Measured by RHC, (and 34 more...)
- 4y agoARNAArena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study ABusiness Wire- Evaluating 2 mg and 3 mg etrasimod in study participants with moderate to severe Crohn's Disease (CD) - Topline data from CULTIVATE Study A on track for Q2 2022 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that it has achieved targe
- 4y agoARNAArena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 23 new employees inducement stock options to purchase an aggregate of 39,400 shares of its common stock and 18,760 inducement
- 5y agoARNAArena Reports Third Quarter Financial Results and Key Program UpdatesBusiness Wire– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout – First participant randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis – Strong liquidity position to support
- 5y agoARNAArena Pharmaceuticals, inc (ARNA) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsARNA earnings call for the period ending September 30, 2021.
- 5y agoARNAArena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options and inducement restricted stock units ("RSUs") to new employees. The inducement stock options and RSUs w
- 5y agoARNAArena Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Corporate Update on November 4Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its third quarter 2021 financial results and provide a corporate update on Thursday, November 4, 2021, after the close of the U.S. financial markets. The Company will host a question and answer sess
- 5y agoARNAEtrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis - NCT05061446ClinicalTrials.govProportion of Participants Achieving Clinical Remission, Proportion of Participants Achieving Endoscopic Improvement, Proportion of Participants Achieving Symptomatic Remission, (and 4 more...)
- 5y agoARNAArena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 20 new employees inducement stock options to purchase an aggregate of 33,340 shares of its common stock and 15,655 inducement
- 5y agoARNAThe Efficacy and Safety of Oral Etrasimod as Therapy for Moderately to Severely Active Crohn's Disease - NCT05033340ClinicalTrials.govKey efficacy assessments, Endpoint definitions:
- 5y agoARNAArena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor ConferencesBusiness Wire– Gastroenterology Investor Call to take place on Tuesday, September 21, 2021 at 10:30 a.m. ET – Dermatology Investor Call to take place on Monday, September 27, 2021 at 11:00 a.m. ET Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced t
- 5y agoARNAArena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement performance restricted stock units ("PRSUs"), and inducement restricted stock units ("RSUs")
- 5y agoARNAArena Reports Second Quarter Financial Results and Key Program UpdatesBusiness Wire– Phase 3 ELEVATE UC 12 trial reached full enrollment; topline data expected Q1 2022 with ELEVATE UC 52 – Liquidity position at ~$1.0 billion as of June 30, 2021 to support continued pipeline progress Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
- 5y agoARNAArena Pharmaceuticals, inc (ARNA) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsARNA earnings call for the period ending June 30, 2021.
- 5y agoARNASecond Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal BiomarkersPR NewswireBRISBANE, Calif., Aug. 5, 2021 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform sg-4-sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announ
- 5y agoARNAArena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its second quarter 2021 financial results and provide a corporate update on Thursday, August 5, 2021, after the close of the U.S. financial markets. The Company will host a live webcast to discuss t
- 5y agoARNAArena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory DiseasesBusiness WireAgreement Provides Arena with Exclusive Option to Acquire Aristea and its CXCR2 Programs post-Phase 2 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Aristea Therapeutics, Inc. today announced a strategic collaboration to advance the clinical developme
- 5y agoARNAArena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that on July 16, 2021, the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an aggregate of 45,200 shares of its common stock and
- 5y agoARNAArena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & DevelopmentBusiness WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Douglas J. Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development, reporting to Amit D. Munshi, President and CEO of Arena. Dr. Manion brings more th
- 5y agoARNAArena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that on June 15, 2021, the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an aggregate of 64,401 shares of its common stock and
- 5y agoARNASteven Schoch Elected to Arena Pharmaceuticals Board of DirectorsBusiness WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Steven Schoch to the Company's Board of Directors and as Chair of the Audit Committee. Mr. Schoch brings more than 20 years of financial and operational leadership and expertis
- 5y agoARNAArena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)Business Wire– EoE affects approximately 135,000 in the US and an estimated 132,000 patients in the EU4 and United Kingdom – Currently no FDA approved therapies in the US for the treatment of EoE Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced th
- 5y agoARNAArena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)Business Wire– Evaluating the safety, tolerability, and efficacy of intravenous (IV) temanogrel for cMVO in adult participants undergoing percutaneous coronary intervention (PCI) – Currently no FDA approved therapies indicated for the treatment of cMVO –
- 5y agoARNACARAJAZZNTECRapid Development of Cannabinoid Based Medicinal Products Reaching New LevelsPR NewswirePALM BEACH, Fla., June 8, 2021 /PRNewswire/ -- The recent pandemic has, as we all know, negatively affected almost every business and financial markets across the globe… and even the seemingly ever increasing Cannabidiol markets. The global COVID-1
- 5y agoARNAA Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis - NCT04915950ClinicalTrials.govRewarming Area Under the Curve (AUC) as Assessed With Infrared (IR) Thermography, Reperfusion AUC as Assessed With Laser Speckle Contrast Imaging (LSCI), Maximum Reduction Following a Cold Challenge as Assessed With IR Thermography, (and 16 more...)
- 5y agoARNAArena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable InvestmentsBusiness Wire- Improvement by two score levels to "A" following the Company's 2021 ESG Report launch underscores Arena's long-term commitment to ESG principles Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that as of 2021, Arena received an MSCI ESG R
- 5y agoARNAArena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that on May 15, 2021, the Compensation Committee of its Board of Directors granted to 22 new employees inducement stock options to purchase an aggregate of 74,905 shares of its common stock and 3
- 5y agoARNAArena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable InvestmentsBusiness Wire- ISS ESG Corporate Rating uses comprehensive research and data to allow institutional investors to identify Environmental, Social and Governance (ESG) risks and seize investment opportunities - Inaugural year of Prime status for Arena, following the
- 5y agoARNAArena Pharmaceuticals Inc (ARNA) Q1 2021 Earnings Call TranscriptEarnings Call TranscriptsARNA earnings call for the period ending March 31, 2021.
- 5y agoARNAArena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the QuarterBusiness Wire– Liquidity position at $1.1 billion as of March 31, 2021 to support continued pipeline progress Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2021.
- 5y agoARNAArena Pharmaceuticals, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 5, 2021 / Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 5, 2021 at 4:30 PM Eastern Time. To listen to the event live or acc
- 5y agoARNAArena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its first quarter 2021 financial results and provide a corporate update on Wednesday, May 5, 2021, after the close of the U.S. financial markets. The Company will host a question and answer session
- 5y agoARNAArena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMXBusiness Wire- Etrasimod 2 mg treatment group achieved statistical significance in the percentage change in weekly peak pruritis (PP-NRS), in the change in Dermatology Life Quality Index (DLQI), and in the change in Patient-Oriented Eczema Measure (POEM) - Etrasi
- 5y agoARNAArena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) ReportBusiness WirePARK CITY, Utah--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the release of its second annual ESG report, outlining the Company’s long-term commitment to the betterment of society, focusing on patients, our employees, the community, the environment, and shareholders. The report builds on Arena’s inaugural report and highlights specific data and examples of the Compa ...
- 5y agoARNAArena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting ExperienceBusiness Wire-Data presentation to be released online at 10:00 AM ET on Friday, April 23, 2021 -Live Q&A session with presenter to be held on Saturday, April 24, 2021 at 3:00 PM ET Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that data from the P
- 5y agoARNAArena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireArena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that on April 15, 2021, the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an aggregate of 50,785 shares of its common stock and